Multivariate analysis of risk factors for cGVHD development
| . | Multivariate analysis . | ||
|---|---|---|---|
| RR . | (95% CI) . | P . | |
| Patient age | |||
| Younger than 5 y | 1.00 | ||
| 5-15 y | 1.39 | (0.93 -2.08) | .1 |
| 15 y or older | 1.82 | (1.06 -3.12) | .03 |
| Donor age | |||
| Younger than 5 y | 1.00 | ||
| 5-20 y | 3.26 | (1.57 -6.77) | .001 |
| 20 y or older | 5.73 | (2.56 -12.8) | .0001 |
| Sex | |||
| Female donor and male recipient vs others | 1.52 | (1.11 -2.07) | .01 |
| Diagnosis | |||
| Malignant vs nonmalignant | 1.80 | (1.13 -2.88) | .01 |
| Donor | |||
| HLA-identical family vs other donors | .69 | (0.41 -1.17) | NS |
| Stem cell source | |||
| CB vs bone marrow + peripheral blood | .07 | (0.03 -0.16) | .0001 |
| Conditioning regimen | |||
| TBI vs chemotherapy | 1.56 | (1.08 -2.26) | .02 |
| GVHD prophylaxis | |||
| Cs-A + MTX + ALG or mAb vs other prophylaxis | 1.55 | (0.92 -2.51) | .08 |
| Acute GVHD grade | |||
| Grade II-IV vs grade 0-I | 2.14 | (1.78 -2.59) | .0001 |
| . | Multivariate analysis . | ||
|---|---|---|---|
| RR . | (95% CI) . | P . | |
| Patient age | |||
| Younger than 5 y | 1.00 | ||
| 5-15 y | 1.39 | (0.93 -2.08) | .1 |
| 15 y or older | 1.82 | (1.06 -3.12) | .03 |
| Donor age | |||
| Younger than 5 y | 1.00 | ||
| 5-20 y | 3.26 | (1.57 -6.77) | .001 |
| 20 y or older | 5.73 | (2.56 -12.8) | .0001 |
| Sex | |||
| Female donor and male recipient vs others | 1.52 | (1.11 -2.07) | .01 |
| Diagnosis | |||
| Malignant vs nonmalignant | 1.80 | (1.13 -2.88) | .01 |
| Donor | |||
| HLA-identical family vs other donors | .69 | (0.41 -1.17) | NS |
| Stem cell source | |||
| CB vs bone marrow + peripheral blood | .07 | (0.03 -0.16) | .0001 |
| Conditioning regimen | |||
| TBI vs chemotherapy | 1.56 | (1.08 -2.26) | .02 |
| GVHD prophylaxis | |||
| Cs-A + MTX + ALG or mAb vs other prophylaxis | 1.55 | (0.92 -2.51) | .08 |
| Acute GVHD grade | |||
| Grade II-IV vs grade 0-I | 2.14 | (1.78 -2.59) | .0001 |